PHARMING GRP SP. ADRS (PHG) - Net Assets
Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) has net assets worth €277.10 Million EUR (≈ $323.96 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€499.96 Million ≈ $584.51 Million USD) and total liabilities (€222.86 Million ≈ $260.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PHARMING GRP SP. ADRS (PHG) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €277.10 Million |
| % of Total Assets | 55.42% |
| Annual Growth Rate | 9.48% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.23 |
PHARMING GRP SP. ADRS - Net Assets Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's net assets have evolved over time, based on quarterly financial data. Also explore PHARMING GRP SP. ADRS total assets for the complete picture of this company's asset base.
Annual Net Assets for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual net assets of PHARMING GRP SP. ADRS from 2021 to 2025. For live valuation and market cap data, see market cap of PHARMING GRP SP. ADRS.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €277.10 Million ≈ $323.96 Million |
+25.35% |
| 2024-12-31 | €221.06 Million ≈ $258.44 Million |
+1.04% |
| 2023-12-31 | €218.78 Million ≈ $255.78 Million |
+6.91% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
+6.08% |
| 2021-12-31 | €192.92 Million ≈ $225.54 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PHARMING GRP SP. ADRS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 18400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €550.09 Million | 198.51% |
| Total Equity | €277.10 Million | 100.00% |
PHARMING GRP SP. ADRS Competitors by Market Cap
The table below lists competitors of PHARMING GRP SP. ADRS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
$762.82 Million |
|
Anshan Senyuan Road Bridge
SHE:300210
|
$763.13 Million |
|
Atal SA
WAR:1AT
|
$763.17 Million |
|
HDC Holdings Co Ltd
KO:012630
|
$763.19 Million |
|
EuroTeleSites AG
F:7YF
|
$762.51 Million |
|
Zhejiang Henglin Chair Industry Co Ltd Class A
SHG:603661
|
$762.51 Million |
|
Metallus, Inc
NYSE:MTUS
|
$762.21 Million |
|
People & Technology Inc
KQ:137400
|
$762.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHARMING GRP SP. ADRS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 221,061,000 to 277,102,000, a change of 56,041,000 (25.4%).
- Net income of 2,851,000 contributed positively to equity growth.
- Other factors increased equity by 53,190,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.85 Million | +1.03% |
| Other Changes | €53.19 Million | +19.2% |
| Total Change | €- | 25.35% |
Book Value vs Market Value Analysis
This analysis compares PHARMING GRP SP. ADRS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 34.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 46.74x to 34.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.30 | €13.90 | x |
| 2022-12-31 | €0.31 | €13.90 | x |
| 2023-12-31 | €0.33 | €13.90 | x |
| 2024-12-31 | €0.32 | €13.90 | x |
| 2025-12-31 | €0.40 | €13.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PHARMING GRP SP. ADRS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.76%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.80x
- Recent ROE (1.03%) is below the historical average (1.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.29% | 8.04% | 0.50x | 2.06x | €-3.30 Million |
| 2022 | 6.68% | 6.65% | 0.48x | 2.08x | €-6.79 Million |
| 2023 | -4.82% | -4.30% | 0.53x | 2.12x | €-32.43 Million |
| 2024 | -5.36% | -3.98% | 0.74x | 1.81x | €-33.95 Million |
| 2025 | 1.03% | 0.76% | 0.75x | 1.80x | €-24.86 Million |
Industry Comparison
This section compares PHARMING GRP SP. ADRS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $353,958,690
- Average return on equity (ROE) among peers: -34.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHARMING GRP SP. ADRS (PHG) | €277.10 Million | 8.29% | 0.80x | $762.66 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more